<DOC>
	<DOC>NCT01360866</DOC>
	<brief_summary>To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)</brief_summary>
	<brief_title>Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Male and Female outpatients 1865 years of age Eligible subjects from Trials 33110227, 33110228 or 33112282: Subjects who completed participation in the Doubleblind Randomization Phase (i.e. Week 14 visit) in Trial 33110227, Trial 33110228, or Trial 33112282 or Subjects who met criteria for a response, but did not meet criteria for remission at Week 14 of either trial Eligible subjects from other Phase 3, Doubleblind, Brexpiprazole MDD trials: â€¢ Subjects who completed the last scheduled visit of the prior Doubleblind Randomized Phase 3 trial. Females who are breastfeeding and/or who have a positive pregnancy test result prior to receiving OPC34712. Subjects with a major protocol violation during the course of their participation in the Doubleblind Randomization Phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Adjunctive Treatment</keyword>
</DOC>